Evecxia, Inc. announced it raised $50,000 in an initial filing from an offering of $150,000

Company

Location

About

Evexcia is the first Company dedicated to realizing the therapeutic potential of Serotonin Synthesis Amplification—building a stronger, more resilient brain serotonin system—to treat central nervous system (CNS) disorders. Evecxia has two Phase 2 clinical-stage drug candidates in development. EVX-101 is being developed as a next-line adjunctive (add-on) therapy for obsessive-compulsive disorder (OCD) and depression patients for whom monotherapy with first-line serotonin reuptake inhibitor antidepressants (e.g., SSRIs such as Prozac®) is inadequate. EVX-301 is being developed as a rescue therapy for patients hospitalized for acute suicidal crisis.